Efficacy and safety of Compound Xuanju Capsules combined with Western medicine in the treatment of type Ш prostatitis with erectile dysfunction: A meta analysis.
- Author:
Bin WANG
1
;
Hao-Cheng LIN
2
;
Yong-Zheng JIAO
3
;
Jin-Ming JIA
1
;
Wei-Guo MA
1
Author Information
1. Department of Andrology， Guang'anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing 100053, China.
2. Department of Urology， Peking University Third Hospital, Beijing 100191, China.
3. Ophthalmology Hospital, China Academy of Traditional Chinese Medicine, Beijing 100040, China.
- Publication Type:English Abstract
- Keywords:
Compound Xuanju Capsules;
type Ш prostatitis;
erectile dysfunction;
meta analysis;
combination therapy
- MeSH:
Male;
Humans;
Prostatitis/complications*;
Erectile Dysfunction/complications*;
Drugs, Chinese Herbal/therapeutic use*;
Capsules;
Randomized Controlled Trials as Topic;
Drug Therapy, Combination;
Treatment Outcome;
Quality of Life;
Phytotherapy
- From:
National Journal of Andrology
2025;31(1):61-68
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically evaluate the effect and safety of the combination of Compound Xuanju Capsules (CXC) and Western medicine (WM) in the treatment of type Ш prostatitis complicated by ED.
METHODS:We searched for randomized controlled trials (RCT) on the treatment of type Ш prostatitis complicated by ED with CXC+WM or WM in the Chinese and English databases CNKI, VIP, Wanfang Digital, Duxiu Academic Search and Chaoxing Electronic Book Information Retrieval, Fangzheng Apabi Electronic Book, Google Scholar Search, Web of Science, Scopus, PubMed, and others from their establishment to April 2024. According to the Cochrane Handbook requirement, we subjected the identified RCTs to meta-analysis using the RevMan 5.3 software.
RESULTS:A total of 16 eligible studies were identified, involving 742 cases treated by combination therapy of CXC+WM and another 742 with WM alone. The results of meta-analysis showed that the rate of clinical effectiveness was dramatically higher in the CXC+WM than in the WM group (P<0.01, MD = 6.19, 95% CI: 4.63－8.28), and so were the IIEF-5 scores (P < 0.004, MD = 2.90, 95% CI: 0.90－4.89), while the quality of life (QOL) scores were significantly lower in the former group than in the latter (P<0.01, MD = －1.94, 95% CI: －2.47－－1.40), and so were the NIH-CPSI scores (P<0.01, MD = －3.92, 95% CI: －4.94－－2.91). No statistically significant difference was reported in the adverse reactions between the two groups (P = 0.12, MD = 0.03, 95% CI: －0.01－0.08). Publication bias analysis on the effectiveness rate of the results revealed an incomplete symmetry between the two sides of the funnel plot, indicating the possibility of publication biases.
CONCLUSION:The combination therapy of CXC+WM is superior to WM alone in the treatment of type Ш prostatitis complicated by ED for its high safety and effect of improving the patients' erectile function, but inferior to the latter in improving the QOL and NIH-CPSI scores of the patients.
